Novacyt S.A. (EPA: ALNOV)

Market Cap	43.31M
Revenue (ttm)	21.89M
Net Income (ttm)	-44.40M
Shares Out	70.54M
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	262,252
Open	0.620
Previous Close	0.627
Day's Range	0.604 - 0.622
52-Week Range	0.493 - 1.590
Beta	-1.86
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 27, 2024

About Novacyt

Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 237
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNOV

Financial Performance

In 2023, Novacyt's revenue was 11.58 million, a decrease of -44.97% compared to the previous year's 21.04 million. Losses were -28.29 million, 9.96% more than in 2022.

Financial numbers in GBP